A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.

Original languageEnglish (US)
Pages (from-to)169-172
Number of pages4
JournalProstaglandins and Other Lipid Mediators
Volume75
Issue number1-4
DOIs
StatePublished - Jan 2005

Keywords

  • Cyclooxygenase-2 inhibition
  • Experimental trial

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Fingerprint Dive into the research topics of 'A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer'. Together they form a unique fingerprint.

Cite this